Last reviewed · How we verify

docetaxel, nedaplatin, and fluorouracil

Sun Yat-sen University · Phase 3 active Small molecule

docetaxel, nedaplatin, and fluorouracil is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development. Also known as: TNF induction chemotherapy.

At a glance

Generic namedocetaxel, nedaplatin, and fluorouracil
Also known asTNF induction chemotherapy
SponsorSun Yat-sen University
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about docetaxel, nedaplatin, and fluorouracil

What is docetaxel, nedaplatin, and fluorouracil?

docetaxel, nedaplatin, and fluorouracil is a Small molecule drug developed by Sun Yat-sen University.

Who makes docetaxel, nedaplatin, and fluorouracil?

docetaxel, nedaplatin, and fluorouracil is developed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

Is docetaxel, nedaplatin, and fluorouracil also known as anything else?

docetaxel, nedaplatin, and fluorouracil is also known as TNF induction chemotherapy.

What development phase is docetaxel, nedaplatin, and fluorouracil in?

docetaxel, nedaplatin, and fluorouracil is in Phase 3.

Related